Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetic Profiling of Pembrolizumab (Keytruda&Reg;) and Nivolumab (Opdiva&Reg;) in Patients With Melanoma and/or Non-Small Cell Lung Cancer: Clinical Validation of a Mass Spectrometry-based Assay

Next Previous
Search
Trial Profile

Pharmacokinetic Profiling of Pembrolizumab (Keytruda&Reg;) and Nivolumab (Opdiva&Reg;) in Patients With Melanoma and/or Non-Small Cell Lung Cancer: Clinical Validation of a Mass Spectrometry-based Assay

Status: Completed
Phase of Trial: Phase 0

Latest Information Update: 08 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
  • Indications Malignant melanoma; Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use

    • Most Recent Events

    • 02 Aug 2023 Status changed from active, no longer recruiting to completed.
    • 02 Mar 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top